Novartis AG Common Stock (NVS)

Growth drivers offset generic erosion as priority brands surge 36% in constant currency.

Novartis (NYSE:NVS) said it returned to sales growth in the second quarter of 2026, supported by strong gains across priority medicines and launches, while reaffirming its full-year outlook despite continued pressure from U.S. generic erosion tied to Entresto. Chief Executive Officer Vas Narasimhan

Novartis (NYSE:NVS) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings

Novartis stock jumped early Tuesday on better-than-expected second-quarter metrics, partially driven by Cosentyx.

Novartis shares rise as strong Q2 demand for key growth drugs offsets generic competition. NVS beats Q2 earnings and reaffirms 2026 targets.

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.

Novartis wins traditional FDA approval for Fabhalta, a first-in-class oral treatment slowing kidney decline in adult IgAN.

According to a new report from Intel Market Research, the global Nitrogen-Containing Bisphosphonate Drugs Market was valued at USD 3.65 billion in 2024 and

Novartis boasts a 26% net margin and a fortress balance sheet, while Teva's turnaround has returned it to profitability, but at what cost to stability?

Not every international ETF is a can't-miss investment opportunity.

VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.

When buying international dividend stocks, diversification is likely the best bet.

Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.

As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.

Novartis acquires Myricx Bio for up to $1.5B to boost its oncology pipeline with a novel next-gen ADC cancer platform. Read more.

Compare portfolio concentration, risk profiles, and long-term growth as these two pharma ETFs take different approaches to capturing sector opportunity.

The best AI stocks might be in totally different industries, companies, and countries.

These international stock ETFs from iShares and Vanguard are very different once you look under the surface.

European stocks are outpacing the S&P 500 in 2026, and ArcelorMittal, Arm Holdings, and Novartis are three Euro Stoxx 50 components with index-beating returns.

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Antares inks Novartis collaboration worth up to $1.9 billion to develop therapies targeting hard-to-treat cancers.

International stocks are trading for a steep discount, and here's a great way to invest.

Teva has been building its comeback, and the latest studies on Austedo and Austedo XR will help further that momentum.

Novartis reports positive Phase 1/2 del-brax data in FSHD, supporting Phase 3 development of a potential disease-modifying therapy.